THERATECHNOLOGIES INC (THTX) Stock Price & Overview
NASDAQ:THTX • CA88338H7040
The current stock price of THTX is 3.39 USD. Today THTX is down by 0%. In the past month the price increased by 4.63%. In the past year, price increased by 171.2%.
THTX Key Statistics
- Market Cap
- 155.872M
- P/E
- N/A
- Fwd P/E
- 24.08
- EPS (TTM)
- -0.19
- Dividend Yield
- N/A
THTX Stock Performance
THTX Stock Chart
THTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to THTX. When comparing the yearly performance of all stocks, THTX is one of the better performing stocks in the market, outperforming 96.37% of all stocks.
THTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to THTX. There are concerns on the financial health of THTX while its profitability can be described as average.
THTX Earnings
On July 9, 2025 THTX reported an EPS of -0.09 and a revenue of 17.73M. The company missed EPS expectations (-482.52% surprise) and missed revenue expectations (-1.91% surprise).
THTX Forecast & Estimates
10 analysts have analysed THTX and the average price target is 4.09 USD. This implies a price increase of 20.63% is expected in the next year compared to the current price of 3.39.
For the next year, analysts expect an EPS growth of 88.56% and a revenue growth -3.03% for THTX
THTX Groups
Sector & Classification
THTX Financial Highlights
Over the last trailing twelve months THTX reported a non-GAAP Earnings per Share(EPS) of -0.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.86% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
THTX Ownership
THTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16 | 410.651B | ||
| AMGN | AMGEN INC | 16.31 | 197.945B | ||
| GILD | GILEAD SCIENCES INC | 16.27 | 180.072B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.6 | 116.919B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 80.868B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.84 | 42.343B | ||
| INSM | INSMED INC | N/A | 30.619B | ||
| NTRA | NATERA INC | N/A | 27.941B | ||
| BIIB | BIOGEN INC | 12.36 | 27.603B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.24 | 21.26B | ||
| MRNA | MODERNA INC | N/A | 21.03B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.746B | ||
| EXAS | EXACT SCIENCES CORP | 308.82 | 19.715B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About THTX
Company Profile
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The company is headquartered in Montreal, Quebec and currently employs 94 full-time employees. The firm offers prescription products for individuals with human immunodeficient virus (HIV) in the United States and its pipeline is focused on specialized therapies designed to address unmet medical needs in both HIV and oncology. The company markets two HIV products, namely EGRIFTA SV and Trogarzo; and has research programs in HIV and oncology. EGRIFTA SV is the therapy for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Trogarzo injection is used with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 who are failing their current regimen. Its pipeline includes Donidalorsen and Olezarsen, and the SORT1+ oncology platform. The firm is also focusing on tesamorelin life-cycle management in lipodystrophy.
Company Info
THERATECHNOLOGIES INC
2015 Peel Street, 11th Floor
MONTREAL QUEBEC H3A 1T8 CA
CEO: Paul Levesque
Employees: 103
Phone: 15143367800
THERATECHNOLOGIES INC / THTX FAQ
What does THTX do?
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The company is headquartered in Montreal, Quebec and currently employs 94 full-time employees. The firm offers prescription products for individuals with human immunodeficient virus (HIV) in the United States and its pipeline is focused on specialized therapies designed to address unmet medical needs in both HIV and oncology. The company markets two HIV products, namely EGRIFTA SV and Trogarzo; and has research programs in HIV and oncology. EGRIFTA SV is the therapy for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Trogarzo injection is used with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 who are failing their current regimen. Its pipeline includes Donidalorsen and Olezarsen, and the SORT1+ oncology platform. The firm is also focusing on tesamorelin life-cycle management in lipodystrophy.
Can you provide the latest stock price for THERATECHNOLOGIES INC?
The current stock price of THTX is 3.39 USD.
Does THTX stock pay dividends?
THTX does not pay a dividend.
How is the ChartMill rating for THERATECHNOLOGIES INC?
THTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of THTX stock?
THERATECHNOLOGIES INC (THTX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for THERATECHNOLOGIES INC?
The Revenue of THERATECHNOLOGIES INC (THTX) is expected to decline by -3.03% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.